title: Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients.
abstract: Hepatitis delta virus (HDV), in association with hepatitis B virus, is responsible for severe acute and chronic hepatitis. Treatment of the infection relies on the long-term administration of high doses of alpha interferon (IFN), and the treatment efficiency is monitored by the detection of anti-HDV immunoglobulin M and HDV genome in serum. Like the case for other chronic viral infections, HDV genome quantification in serum should be useful for the follow-up of infected patients. The aims of this study were to develop a quantitative assay for the detection of any type of HDV in serum and to evaluate the benefit of HDV RNA quantification for the follow-up of chronically infected patients receiving IFN. A real-time reverse transcription-PCR assay was developed to quantify the HDV RNA load in serum. Its efficacy was evaluated with 160 serum samples, 76 of which were collected from 11 chronically infected patients who were treated with pegylated IFN. The assay was sensitive (100 copies/ml of serum) and efficient for all HDV types, including type 3 and the recently described types 5, 6, and 7. The viral load determinations for treated patients allowed us to identify different profiles of virological responses to IFN therapy with more accuracy than that attainable with the qualitative approach. In conclusion, we have developed a quantitative HDV RNA assay for serum which is adapted to the follow-up of antiviral treatment for patients infected with any HDV type. The assay will help us to understand the natural history of HDV infection and to define guidelines for the management of chronic delta hepatitis.
authors.affiliation: Laboratoire de Bactériologie-Virologie-Hygiène, Hôpital Avicenne, EA3604, Assistance Publique-Hôptaux de Paris, Université Paris 13, Bobigny, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Le Gal
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Gordien
authors.forename: Dissou
authors.initials: D
authors.lastname: Affolabi
authors.forename: Thomas
authors.initials: T
authors.lastname: Hanslik
authors.forename: Chakib
authors.initials: C
authors.lastname: Alloui
authors.forename: Paul
authors.initials: P
authors.lastname: Dény
authors.forename: Elyanne
authors.initials: E
authors.lastname: Gault
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D016384:Consensus Sequence; D005260:Female; D006679:HIV Seropositivity / Q000150:complications; D003699:Hepatitis D / Q000097:blood / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D003698:Hepatitis Delta Virus / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D012367:RNA, Viral / Q000097:blood*
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D007372:Interferons